Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
By Tony Dutra
July 21 — Balloon catheter maker AngioScore Inc. lost a $20 million award for breach of fiduciary duty after the U.S. Court of Appeals for the Federal Circuit ruled July 21 that a lower court didn't have jurisdiction in the case ( AngioScore, Inc. v. TriReme Med., LLC , 2016 BL 233848, Fed. Cir., No. 2016-1126, 7/21/16 ).
AngioScore had eased co-founder Eitan Konstantino out of the company, and Konstantino developed the Chocolate balloon catheter with his new outfit, TriReme Medical LLC. The U.S. District Court for the Northern District of California went ahead and took the case when AngioScore complained that Konstantino was supposed to have offered it the technology first. This was a state law matter, but the federal trial court took the case because AngioScore had also included a claim under federal patent law.
However, the Federal Circuit, in a nonprecedential opinion, said that the two issues were unrelated, and Judge Yvonne Gonzalez Rogers shouldn't have exercised supplemental jurisdiction over the state law piece of the case.Source Material:
U.S. Patent:No. 7,691,119
The fiduciary duty breach charge required Rogers to assess only whether Chocolate was a “corporate opportunity” for AngioScore, the court said. Although she needed a general understanding of how Chocolate operated to know whether it was in the same line of business as AngioScore's AngioSculpt devices, there was no overlap between that underlying set of facts and what the patent infringement claim called for, the court said.
The appeals court reversed the judgment and remanded the matter back to the trial court with instructions to dismiss the state law claims.
In the lower court, a jury had found that certain claims of AngioScore's U.S. Patent No. 7,691,119 were invalid and not infringed by Chocolate.
AngioScore is a wholly owned subsidiary of Spectranetics Corp. of Colorado Springs, Colo. In a press release, Spectranetics said it was confident in the merits of the case and is evaluating its next steps, which might include a state court filing of the breach complaint.
TriReme is a subsidiary of Singapore-based QT Vascular Ltd., a co-defendant in the case.
Judge Todd M. Hughes wrote the court's opinion, which was joined by Judges Jimmie Reyna and S. Jay Plager.
Quinn Emanuel Urquhart & Sullivan LLP represented AngioScore. Arnold & Porter LLP represented TriReme.
To contact the reporter on this story: Tony Dutra in Washington at email@example.com
To contact the editor responsible for this story: Mike Wilczek at firstname.lastname@example.org
Text is available at http://src.bna.com/gZZ.
Copyright © 2016 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)